1. Post in a contract the second	N	
Admit Stand Frank Stand Store	ROBBONTA	
a de la transferia de la comte		
	Attorney General of California	
2	LAURA J. ZUCKERMAN, SBN 161896	
	Supervising Deputy Attorney General	
	DENNIS A. RAGEN, SBN 106468	FILED ALAMEDA COUNTY
	MEGAN K. HEY, SBN 232345	
4	Deputy Attorneys General	JAN 2 7 2022
	300 South Spring Street, Suite 1702	
5	Los Angeles, CA 90013	CLERK OF THE OPERIOR COURT
Starthered	Telephone: (213) 269-6344	By
6	E-mail: Megan.Hey@doj.ca.gov	Deputy
an New Arts in the	Attorneys for the People of the State of Californ	la
7		
	JILL RAVITCH	그는 것 이 한 것은 이것을 알아야 한 것을 받았다.
8	District Attorney, County of Sonoma	
a provensi se provensi se	CAROLINE L. FOWLER, SBN 110313	an and a start of the second st
9	Deputy District Attorney	
	2300 County Center Dr., Ste. B-170	
10	MATTHEW CHEEVER, SBN 191783	
	Deputy District Attorney	
11	Santa Rosa, CA 95403	
	Telephone: (707) 565-3161	
12	E-mail: matthew.cheever@sonoma-county.org	
S. B	E-mail: caroline.fowler@sonoma-county.org	
13		
	(Additional Counsel on following page)	
14		
15	SUPERIOR COURT OF TH	
15	SUPERIOR COURT OF THE	E STATE OF CALIFORNIA
16	COUNTY OF	
10	COUNTOR	ALAMEDA
17		1
17	PEOPLE OF THE STATE OF	Core No. BC19012552
18	CALIFORNIA,	Case No. RG18912553
	Plaintiff,	CONSENT JUDGMENT
19	v.	CONSENT JUDGWIENT
20	MEAD JOHNSON NUTRITION	Action filed: June 7, 2018
	COMPANY, a Delaware corporation;	Dept: 17
21	MEAD JOHNSON & COMPANY, LLC, a	Judge: Hon. Frank Roesch
Sec. 1. All and the	Delaware limited liability company; NURTURE, INC. (dba HAPPY FAMILY),	
22	a Deleware componetion: DEDDICO	
₩ 1 23	a Delaware corporation; PERRIGO COMPANY, a Delaware corporation; PBM	
<u>n</u> 23	PRODUCTS, LLC, a Delaware limited	
0	liability company; PBM NUTRITIONALS,	1 4 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1
<u> </u>	LLC (dba Perrigo Nutritionals), a Delaware	
	limited liability company; TARGET	
25	CORPORATION, a Minnesota corporation;	
S ~	TARGET BRANDS, INC., a Minnesota	
8 26	corporation; WALMART, INC. (fka WAL-	
5	MART STORES, INC.), a Delaware	
27	corporation; and DOES 1-50, inclusive,	
28		
- 28 - 28	Defendants.	
8		
Ω (and the second se	1
L0:E0 24 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:09:00 12:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:00 10:	CONSENT JUDGME	NT (RG18912553)

onically Received 1 2/08/2021 03:07 PM

an in the method and a sub-	and a second	الم الم الم مراجع بين المراجع (1994) المحافظ المحافظ المراجع (1994) المحافظ المحافظ المحافظ المحافظ المحافظ الم
1 , 1 ,	Additional Counsel for the People (continued from	preceding page):
2	Never E O'Merrow	I on Francis
	NANCY E. O'MALLEY District Attorney, County of Alamoda	LORI FRUGOLI
	District Attorney, County of Alameda MATTHEW L. BELTRAMO, SBN 184796	District Attorney, County of Marin ANDRES PEREZ, SBN 186219
	Deputy District Attorney	Deputy District Attorney
4	1225 Fallon St., 9th Floor	Deputy District Automey
Marchen Richt State - 1	Oakland, CA 94612	Deputy District Attorney
5	Telephone: 510-383-8600	3501 Civic Center Drive, Room 145
	E-mail: matt.beltramo@acgov.org	San Rafael, CA 94903
6.	1 main matteoritanio Guogoviorg	Telephone: (415) 473-3072
and the second second	JEANNINE PACIONI	E-mail: aperez@marincounty.org
7.	District Attorney, County of Monterey	E-mail: AChavez@marincounty.org
	CHRISTOPHER JUDGE, SBN 274418	
8	Deputy District Attorney	ALLISON HALEY
	1200 Aguajito Road, Room 301,	ALLISON HALEY District Attorney, County of Napa
9	Monterey, CA 93940	KATY YOUNT SBN 279550
	Telephone: (831) 647-7770	Deputy District Attorney
- 10	E-mail: andersonal@co.monterey.ca.us	PATRICK COLLINS, SBN 253872
	E-mail: judgec@co.monterey.ca.us	Deputy District Attorney
11	,	1127 First Street, Suite C
10	JEFFREY ROSEN	Napa, CA 94559
12	District Attorney, County of Santa Clara	Telephone: (707) 299-1452
12	JENNIFER DENG, SBN 206285	E-mail: katy.yount@countyofnapa.org
13	Deputy District Attorney	E-mail: patrick.collins@countyofnapa.org
14	70 W. Hedding St, West Wing	
14	San Jose, CA 95110	STEPHANIE BRIDGETT
15	Telephone: (408) 792-2818	District Attorney, County of Shasta
15	E-mail: jdeng@dao.sccgov.org	ANAND "LUCKY" JESRANI, SBN 238252
16		Senior Deputy District Attorney
	JEFF ROSELL District Attorney County of Sente Cruz	1355 West Street
17	District Attorney, County of Santa Cruz DOUGLAS ALLEN, SBN 99239	Redding, CA 96001
	Assistant District Attorney	Telephone: (530) 245-6300 E-mail: ljesrani@co.shasta.ca.us
18	Francisca Allen, SBN 99402	L-man. ijestam@co.snasta.ca.us
	Assistant District Attorney	KRISHNA A. ABRAMS
19	701 Ocean Street, Suite 200	District Attorney, County of Solano
1	Santa Cruz, CA 95060	DIANE NEWMAN, SBN 179926
20	Telephone: (831) 454-2930	Deputy District Attorney
- 0	E-mail: douglas.allen@santacruzcounty.us	675 Texas Street, 4 th Floor, #4500
21	E-mail: Francisca.Allen@santacruzcounty.us	Fairfield, CA 94533
	Ŭ .	Telephone: (707) 784-6903
22		E-mail: dmnewman@solanocounty.com
22		
23	а аз ж. а с	TODD SPITZER
24		District Attorney, County of Orange
24		ALICIA BERRY, SBN 228367
25		Senior Deputy District Attorney
25		300 N. Flower St.
26		Santa Ana, CA 92703
20		(714) 834-3600
27		Email: Alicia.Berry@da.ocgov.com
28	- · · · · · · · · · · · · · · · · · · ·	
	2	

~ ~ ~

1. INTRODUCTION

3 This stipulation and proposed consent judgment ("Consent Judgment") is entered 1.1. 4 into between (1) Plaintiff in this action, the People of the State of California (the "People"), by 5 and through Rob Bonta, Attorney General ("Attorney General"); Nancy E. O'Malley, District 6. Attorney of Alameda County; Lori E. Frugoli, District Attorney of Marin County; Jeannine 7 Pacioni, District Attorney of Monterey County; Allison Haley, District Attorney of Napa County; 8 Todd Spitzer, District Attorney of Orange County; Jeffrey F. Rosen, District Attorney of Santa 9 Clara County; Jeffrey Rosell, District Attorney of Santa Cruz County; Stephanie Bridgett, District 10 Attorney of Shasta County; Krishna Abrams, District Attorney of Solano County; and Jill R. 11 Ravitch, District Attorney of Sonoma County (collectively, "District Attorneys"): (2) Community 12 Science Institute ("CSI"), which is the Plaintiff in the two related actions described in Section 13 2.3, below; and (3) the following Defendants: Perrigo Company; PBM Products, LLC; and PBM 14 Nutritionals, LLC (collectively, "Settling Defendants"). The Plaintiffs and the Settling 15 Defendants are referred to as the "Parties. Except where otherwise indicated, the term "Plaintiff" 16 refers collectively to the People and CSI.

17 1.2. The Parties enter into this Consent Judgment without a trial. Nothing in this
18 Consent Judgment constitutes an admission by Settling Defendants regarding any issue of law or
19 fact. This Consent Judgment sets forth the agreement and obligations of the Parties and, except
20 as specifically provided below, it constitutes the complete, final and exclusive agreement among
21 the Parties and supersedes any prior agreements among the Parties.

22

1

2

2. BACKGROUND, JURISDICTION AND PURPOSE.

23 2.1. On July 12, 2018, the People filed a complaint for civil penalties and injunctive
24 relief, in this action, for violations of the Safe Drinking Water and Toxic Enforcement Act of
25 1986 (Health and Safety Code section 25249.5 et seq. ["Proposition 65"]) and the Unfair
26 Competition Law (Business and Professions Code section 17200 et seq.) This action is entitled
27 People of the State of California v. Mead Johnson, et al., Alameda County Superior Court Action
28 No. RG18912553 (the People's "Complaint"). The People's Complaint names Settling

3 Consent Judgment (RG18912553) Defendants and three of its retail customers who sold the products, Walmart, Target Corporation and Nurture, Inc. It alleges that Settling Defendants manufactured and sold infant and toddler formula products to customers in California that contained lead; and that the lead was present in concentrations that required Proposition 65 warnings. The People further alleged that the claimed violations of Proposition 65 also constituted violations of the Unfair Competition Law.

2.2. Community Science Institute (CSI) is a non-profit organization whose mission is to unite consumers and neighbors to reform government and industry practices for a toxic-free future. CSI's work involves empowering residents and consumers to test their homes and communities for toxic chemical hazards and to take action to hold corporations accountable.

10 2.3. Prior to the People's filing of their Complaint, on January 2, 2018, CSI filed two 11 complaints, in the related actions, seeking civil penalties and injunctive relief against Settling 12 Defendants and two of their retail customers - Target Corporation in one case and Walmart in the 13 other case. Like the People, CSI alleges violations of the Safe Drinking Water and Toxic 14 Enforcement Act of 1986 (Health and Safety Code section 25249.5 et seq. ["Proposition 65"]). 15 The actions are: Community Science Institute v. Target Corporation, et al., Alameda County 16 Superior Court No. RG1887565 and Community Science Institute v. Wal-Mart Stores, Inc., et al.), 17 Alameda County Superior Court No. RG1887567 (collectively the two complaints are referred to 18 as the "CSI Complaint"). The CSI Complaint alleges that infant and toddler formula products 19 manufactured and sold by Settling Defendants to the two retail customers in California contained 20 lead in concentrations causing exposure that required Settling Defendants to provide warnings on 21 the products pursuant to Proposition 65.

22 2.4. The Complaints of the People and of CSI will be referred to collectively as
23 "Complaints."

24 2.5. Settling Defendants manufacture several different infant and toddler formulas,
25 made for a diverse mix of customers nationwide. Their retail customers in turn purchase the
26 formulas and sell them to consumers under their own private labels.

28

27

1

2

3

4

5

7

8

9

2.6. Settling Defendants deny the allegations made in both the People's and CSI's Complaints. They further deny that their formula products contain levels of lead that cause exposures that violate Proposition 65 and require warnings.

2.7. For purposes of this Consent Judgment, the Parties stipulate that: (a) this Court has jurisdiction over the allegations of violations contained in the Complaint; (b) this Court has personal jurisdiction over Settling Defendants as to the acts alleged in the Complaint; (c) venue is proper in Alameda County; and (d) this Court has jurisdiction to enter this Consent Judgment as a full and final resolution of all claims which were or could have been raised in the Complaints based on the facts alleged therein.

2.8. Settling Defendants waive the right to a hearing and trial on the matters alleged in
the Complaint. Settling Defendants agree not to challenge or object to entry of this Consent
Judgment by the Court unless the People have notified them in writing that the People or CSI no
longer support entry of the Consent Judgment, or that the People seek to modify the Consent
Judgment. Settling Defendants agree that this judgment may be entered by the court by ex parte
application without further notice to Settling Defendants.

2.9. The Parties agree not to challenge this Court's jurisdiction to enforce the terms of
this Consent Judgment once it has been entered, and this Court maintains jurisdiction over this
Consent Judgment for that purpose.

2.10. The Parties enter into this Consent Judgment as a full and final settlement of all
claims alleged in the Complaints relating to the presence of lead in the Covered Products, as
defined herein. By execution of this Consent Judgment and agreeing to provide the relief and
remedies specified herein, Settling Defendants do not admit any violations of Proposition 65, the
Unfair Competition Law, other statutory, common law or equitable law or requirements. Nothing
in this Consent Judgment is intended to be an admission of any issue of law or fact.

25

28

1

2

3

4

5

6

7

8

9

3. **DEFINITIONS**

3.1. "Covered Products" shall mean the Named Products and any other Formula
Products in powder form manufactured by Settling Defendants that they sell in, or distribute for

5

sale to, California, either directly, or to a third-party retail customer who Settling Defendants know or reasonably should know will ship for sale directly to California consumers.

1

2

3

4

5

.6

7

8

3.2. The "Effective Date" of this Consent Judgment shall be the date on which the Consent Judgment is entered as a judgment by the Court.

3.3. "Formula Product" shall mean a formulation of either milk or soy protein combined with various additional ingredients, all manufactured to create a finished product in powder form and packaged for sale and to be reconstituted with water for consumption by infants or toddlers pursuant to labeling instructions.

9 "Independent Food Processing Auditor" or "Independent Auditor" shall mean an 3.4. 10 independent auditing company, foreign or domestic, that: (i) has extensive knowledge of good 11 manufacturing practices in the food processing industry; (ii) has sufficient experience in 12 inspecting food processing facilities to ensure compliance with good manufacturing practices and 13 with the Hazard Analysis and Critical Control Points ("HAACP") food safety management 14 system; (iii) which is (1) certified as an International HACCP Alliance lead Instructor; (2) 15 certified as a SQF HACCP Lead Auditor or SQF Consultant; (3) holds an NEHA Certified Professional - Food Safety (CP-FS) Credential; (4) is certified as a Food Scientist by Institute of 16 17 Food Technology; or (5) has equivalent qualifications; and (iv) has submitted a satisfactory 18 resume of its qualifications to the People. Upon request, the People will provide to the Settling 19 Defendants a list of Independent Food Processing Auditors who have previously submitted their 20 qualifications to the Attorney General, whose qualifications are up to date, and who are deemed 21 to meet the criteria set forth in this Paragraph. The Settling Defendants, however, may select any 22 Independent Food Processing Auditor who meets these criteria. If the Independent Food 23 Processing Auditor's qualifications do not meet these criteria, the People may instruct Perrigo to 24 select a different Independent Food Processing Auditor.

25 3.5. "Internal Auditor" shall mean an employee or other agent of Settling Defendants 26 who has received training adequate to undertake the responsibilities set forth in Section 4 and 5 of 27 this Consent Judgment, including, without limitation, the requirement to provide complete and 28 accurate certifications as required by Section 4 and 5 of this Consent Judgment. The Internal

Auditor may be replaced from time to time by another equally qualified employee or agent of Settling Defendants.

3.6. "Maximum Lead Level" shall mean 7 parts per billion (ppb) for soy based formulas and 5 ppb for all other Covered Products. A Covered Product satisfies the Maximum Lead Level if testing pursuant to this Consent Judgment as set forth below demonstrates that it has a lead concentration of no more than 7 ppb for soy-based formulas, and 5 ppb for all other Covered Products.

8 3.7. "Target Lead Level" shall mean 4 ppb or such lower lead level as may be set for a 9 Covered Product, or group of similar Covered Products, by the Internal Auditor pursuant to 10 Section 5.1(3) below. The "Target Level" for a Covered Product may be adjusted to a level above 11 4 ppb in the event that : (a) a significant, unavoidable and prolonged disruption occurs in the 12 supply chain of ingredients Settling Defendants use to manufacture that Covered Product; (b) if 13 the lead level in a new ingredient formulation of a Covered Product cannot be feasibly lowered to 14 an amount that would allow that Covered Product to meet the Target Lead Level; or (c) the 15 ingredients supplied for soy-based product are constituted such that, even with Settling 16 Defendants' ongoing best efforts, it produces a result exceeding 4 ppb.

17

22

23

1

2

- 3

5

7

4

3.8. Test results are defined as follows:

3.8.1. An "Outlier Result" is a result of laboratory testing for a Covered Product
conducted pursuant to Section 4.2.2 or 4.2.3 that exceeds the Maximum Lead Level.

3.8.2. A "Final Test Result" is a result of laboratory testing for a Covered Product
that is:

 conducted pursuant to Section 4.2.2 or 4.2.3 and does not exceed the Maximum Lead Level; or

(2) becomes the Final Test Result pursuant to the provisions of Section 4.3.1.
3.9. For analysis of the Covered Products, "Qualified Laboratory" shall mean a
laboratory that has demonstrated proficiency to conduct lead analysis on the Covered Products
using Inductively Coupled Plasma Mass Spectrometry ("ICP-MSA). A Qualified Laboratory must

28

7 Consent Judgment (RG18912553) meet the specifications set forth in Title 27, California Code of Regulations section 25900(b), and the Laboratory Standards set forth in Exhibit B.

3.10. "Named Products" shall mean the formula products named in the Complaints filed by the People and by CSI: 1) Nurture HappyTot Organic Milk Drink; 2) Nurture HappyTot Grow & Shine Toddler Formula; 3) Target Up & Up Toddler Beginnings; and 4) Walmart Parent's Choice Toddler Beginnings.

7

1

2

3

4

5

6

INJUNCTIVE RELIEF: LEAD REDUCTION MEASURES

8 4.1. After the Effective Date, and excluding Covered Products manufactured before 9 that date, Settling Defendants shall not manufacture for sale to, distribute into, or sell in, 10 California, any Formula Products that do not comply with the Maximum Level, either directly, or to a third-party retail customer who Settling Defendants know or reasonably should know will 12 sell the products in, or ship for sale directly to, California.

13

11

4.2. **Compliance Testing**

14 4.2.1. A Covered Product complies with the Maximum Lead Level if testing by a 15 Qualified Laboratory pursuant to Sections 4.2.2 through 4.2.4 so establishes. Each lot of finished 16 Covered Products shall be placed on hold until the testing is completed and the results show the 17 lot satisfies the Maximum Lead Level; the lot of finished product then can be released for sale.

18 4.2.2. To determine compliance for a production lot, Settling Defendants shall 19 collect six (6) samples within the lot of finished Covered Products. A Covered Product complies 20 with the Maximum Lead Level if the samples, or a composite of those samples, tested have a lead 21 concentration below the Maximum Lead Level.

22 4.2.3. For each newly formulated Covered Product, Settling Defendants shall test 23 the first six (6) commercial production lots on a hold and release basis, using the procedure set 24 forth in Section 4.2.2.

25 4.2.4. Settling Defendants shall then at a minimum conduct surveillance of each 26 Covered Product by annual testing of representative subsequent production lots, using the 27 procedure set forth in Section 4.2.2, in compliance with Exhibit A, Section G.

28

8

4.3. Outlier Test Results

1

2

3

4

5

6

7

8

9.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

4.3.1. If the result of the testing pursuant to Paragraphs 4.2.2 to 4.2.4 yields an Outlier Result, Settling Defendants shall have the option to subject this Outlier Result to validation testing before it is considered a Final Test Result. The validation process shall be concluded within thirty (30) days, and shall be made up of two steps:

1. The laboratory from which the Outlier Result in question was obtained shall, at the option of Settling Defendants, evaluate and check the instrument, equipment, supplies and environment used during the testing of the samples to evaluate whether factors in connection with the testing of samples could be a factor in the Outlier Result. The laboratory shall further review the testing methods, including areas of potential contamination with testing equipment, testing processes, validation procedures and potential operator error. If the laboratory determines the Outlier Result was caused by a potential error on its part and explains the basis for this determination to Settling Defendant in writing, the result shall not be considered valid for the purposes of this Consent Judgment. It will be discarded and must be replaced with a new test result from sampling conducted pursuant to the requirements of Section 4.2.2 above. This replacement test must be obtained within thirty (30) days of the date that the original erroneous test result is discarded, and the results of this testing shall become the Final Test Result.

2. If an evaluation by the laboratory in paragraph 4.3.1(1) does not determine that there was laboratory error with regard to the Outlier Result, Settling Defendants, at their option, may test a minimum of four (4) subsamples within the lot that exceeded the Maximum Lead Level. If such additional testing is performed, the arithmetic mean of all the test results shall be deemed the Final Test Result for the production lot, and this result will become the Final Test Result for purposes of the Consent Judgment.

3. If Settling Defendants choose not to exercise the option to retest the original sample, or any additional samples as set forth herein in Section 4.3, then the original Outlier Result shall become the Final Test Result for the production lot.

n para para si si s 1 .	4.4. Covered Products That Meet or Exceed Maximum Lead Level
	4.4.1. If the Final Test Result does not Exceed the Maximum Lead Level, then
and 1997 - 3	the Covered Product in the lot in question shall be considered in compliance.
	4.4.2. If the Final Test Result exceeds the Maximum Lead Level, Settling
5	Defendants shall follow the requirements of Section 4.5 below.
the short of the state of a	4.5. Final Test Results in excess of the Maximum Lead Level.
7	4.5.1. If the Final Test Result exceeds the Maximum Lead Level, Settling
8	Defendants shall cure the exceedance as follows:
9	4.5.2. Settling Defendants shall not release any batch of the specific lot of
10	Covered Product for sale to California.
11	4.5.3. Settling Defendants shall have ninety (90) days from the date that a Final
12	Test Result that shows an exceedance of the Maximum Lead Level to investigate the potential
13	causes of the exceedance in the specific lot in question of the Covered Products, to implement
14	corrective action to bring the Covered Product in question into compliance with the Maximum
15	Lead Level, and to produce a written report, as follows:
16	(1) The Internal Auditor shall promptly investigate the cause or causes
17	of the Outlier Result;
18	(2) Settling Defendants shall contact the Independent Food Quality
19	Auditor and request a meeting with that Auditor, and the
20	Independent Auditor shall review the test results and investigate
21	the source, or sources, of the Outlier Result in conjunction with the
22	Internal Auditor if: (a) the Final Test Result exceeds 7 ppb, (b)
23	within the preceding two (2) years there have been one or more
24	Final Test Results that exceeded the Maximum Lead Level
25	applicable to that Covered Product, or (c) the Internal Auditor
26	determines that consultation with the Independent Auditor is
27	appropriate. Settling Defendants will, in such an instance, comply
28	with the Independent Food Quality Auditor's recommendations and
	10
	CONSENT JUDGMENT (RG18912553)

- F. 34

1 e. d.

1.400

and the second

advice to establish compliance with the Consent Judgment for the Covered Product;

The Internal Auditor shall prepare a report outlining the cause(s) of the Outlier Result and the corrective steps that will be implemented going forward, including the steps recommended by the Internal Auditor and, if applicable, the Independent Auditor, to ensure the Covered Product's compliance with the Consent Judgment.

4.5.4. The Internal Auditor will also confirm that testing of samples from the first five (5) production lots subsequent to the report required by Section 4.5.3(3) has been conducted pursuant to Sections 4.2 and 4.3 above, and that the results do not exceed the Maximum Lead Level.

(3)

12 4.6. In addition to the requirements of Section 4.5.3(2), as part of its annual 13 certification required by Section 5.2 of this Consent Judgment for Covered Products intended for 14 sale in, or sold in, California, Settling Defendants will consult with the Independent Auditor to 15 review their procedures pertaining to the feasibility of keeping lead levels of soy-based products 16 at 5 ppb or lower. If the results of testing conducted pursuant to the Sections 4.2 through 4.3 or 17 Section 7 of this Consent Judgment confirms the Final Test Result of a soy-based Covered 18 Product has exceeded 5 ppb within the preceding two (2) years, or indicates that the level for a 19 soy-based Covered Product is likely to exceed 5 ppb, Settling Defendants will consult with the 20 Independent Auditor as part of that annual certification process to review those test results and the 21 feasibility of meeting the 5 ppb level, and discuss and implement to the extent feasible his or her 22 recommendations, if any, for minimizing the lead levels in those Covered Products.

23

Shandaria - 1.

restriction of 3

2

-4

5

6

7

8

9

10

11

5. INTERNAL AUDITOR

5.1. Settling Defendants shall appoint an Internal Auditor. Within sixty (60) days of the
Effective Date and annually thereafter on each anniversary of the Effective Date, the Internal
Auditor will provide written certification to the People that:

27 28

 the Covered Products, when tested pursuant to Sections 4.2.2 through 4.2.4 of this Consent Judgment, do not contain lead in excess of the Maximum Lead Level;

11

	2. the Auditor has recommended, and Settling Defendants have implemented, procedures
2 ·	for the testing of Representative Product Samples (as that term is defined in Exhibit A)
й ла циянын 1936- 3 1	of the Covered Products by a Qualified Laboratory to ensure that they satisfy the
	Maximum Lead Level;
1977 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -	3. The Internal Auditor has conducted a lead contribution exercise (that evaluates any
	product ingredients that can contribute a significant amount of lead to a Covered
	Product or group of similar Covered Products). Based on this exercise and the Internal
8	Auditor's review of the lowest lead levels than can be achieved by commercially
	reasonable means, the Internal Auditor has set a Target Lead Level of 4 ppb or less for
	each Covered Product or group of similar Covered Products.
11	4. Settling Defendants' control process is adequate to keep the Covered Products below
12	the Target Lead Level.
13	5. All ingredients that may contribute significant amounts of lead to the Covered Product
14	have been sourced to satisfy the applicable Target Lead Level. These ingredients shall
15	be identified in connection with Settling Defendants' regular risk assessment required
16	as part of its Hazard Analysis and Critical Control Points ("HACCP") program.
17	6. Good Manufacturing and robust ingredient sourcing practices have been implemented
18	to ensure that the lead content in the Covered Products (i) has been reduced to the
19	lowest level commercially feasible and (ii) does not exceed the applicable Target Lead
20	Level.
21	7. The Internal Auditor has reviewed operations every six (6) months to obtain
22	laboratory testing of the Covered Products and to ensure that requirements of this
23	Section 5 are continuously satisfied.
24	8. The Internal Auditor has evaluated any commercially feasible ways to further reduce
25	the lead content in the Covered Products, including, without limitation, the selection of
	appropriate alternative ingredients or ingredient sources, and the resulting
27	recommendations from the Auditor have been implemented. In completing this task,
28	the Internal Auditor shall consult annually with an Independent Food Quality Auditor
	12

•

l

who shall provide advice on commercially feasible ways, including ingredient sourcing, to further reduce the lead content in the Covered Products and their ingredients.

5.2 The certification shall be in the form set forth in Exhibit A.

 $_{
m sol}$, $_{
m sol}$

2

5

11

14

15

4

6

7

Sec. 2.

5.3 The first such annual certification will be reviewed by the Independent Auditor, and Settling Defendants will provide the Independent Auditor with site access and data as necessary for the completion of this review.

8 5.4 The Internal Auditor shall continue to provide these annual certifications to the 9 People for a period of five (5) years following the Effective Date of this Consent Judgment. After 10 providing the last of the annual certifications, Settling Defendants may cease providing further certifications. Settling Defendants shall, however, remain in compliance with the requirements of 12 this Consent Judgment, and the Internal Auditor will, on request, provide the People with 13 documentation showing compliance with Sections 4.2, 4.3, 4.5.3, 4.5.4, 4.6 and 5.1, above.

6. PAYMENTS

6.1

Civil Penalties and Restitution.

16 6.2 Pursuant to California Health and Safety Code section 25249.12, Settling 17 Defendants agrees to pay civil penalties in the total sum of \$72,500, as set forth in Exhibit C, 18 which is due to be paid within thirty (30) days of the Effective Date. Pursuant to Health and 19 Safety Code sections 25249.12, seventy-five percent (75%) of this penalty shall be paid to the 20 Office of Environmental Health Hazard Assessment and twenty-five percent (25%) of this 21 penalty will be divided evenly between the Attorney General and CSI.

22 6.3 Pursuant to California Business and Professions Code section 17206, Settling 23 Defendant agrees to pay civil penalties in the amount of \$72,500, which is due to be paid within 24 thirty (30) days of the Effective Date, and which shall be payable as set forth in Exhibit C. 25 Pursuant to Government Code section 26506, these penalties shall be distributed in equal amounts 26 among the counties whose District Attorneys appeared for the People in this matter.

27 6.4 Fees and Costs. Within thirty (30) days of the Effective Date, Settling Defendants 28 shall also make the following payments as stipulated attorneys' fees and costs:

13

6.4.1 The Attorney General: \$45,000

6.4.2 The District Attorneys: \$30,000 (to be allocated and distributed pursuant to agreement among the District Attorneys involved in this action.)

6.4.3 CSI: \$140,000

6.4.4 These payments shall be distributed as set forth in Exhibit C.

6.5 <u>Documentation from CSI</u>. CSI will provide the Court with the documentation required by 11 Cal Code Regs. section 3201, subdivision (e), in support of the fees and costs it will recoup pursuant to Section 6.2.3, above.

6.6 <u>Copies of checks</u>. Settling Defendants will cause copies of each and every check
 and confirmation of each wire transfer pursuant to this Consent Judgment to be sent to: Megan
 Hey, Deputy Attorney General, Office of the CA Attorney General, 300 South Spring Street, Los
 Angeles, CA 90013.

13

1

2

3

4

5

6

7

8

7. ENFORCEMENT

14 7.1 The People and CSI will monitor Settling Defendants' compliance with the terms 15 of this Consent Judgment. The People and CSI may conduct random testing of Covered Products 16 to ensure Settling Defendants are in compliance with those terms. The People or CSI may, by 17 motion or application for an order to show cause before this Court, enforce the terms and 18 conditions of this Consent Judgment and seek redress for any violations of this Consent Judgment 19 (including, without limitation, violations based on evidence that a Covered Product sold in 20 California contained lead concentrations in excess of the Maximum Lead Level after the Effective 21 Date). If the People or CSI produce evidence that one or more samples of a Covered Product sold 22 in California after the Effective Date contain(s) lead concentrations in excess of the Maximum 23 Lead Level, Settling Defendants will consult with the Independent Auditor to review those test 24 results and will implement to the extent feasible his or her recommendations, if any, for 25 minimizing the lead levels in those Covered Products. In any enforcement proceeding filed 26 pursuant to this section, the People or CSI, as applicable, may seek whatever fines, costs, 27 penalties, or remedies are provided by law for failure to comply with the Consent Judgment. 28 Where such violations of this Consent Judgment also constitute a violation of Proposition 65, the

14

Unfair Competition Law, the False Advertising Law (Bus. & Prof. Code, § 17500 et seq.), or other laws, independent of this Consent Judgment, the People or CSI may seek in another action whatever fines, costs, penalties, or remedies are provided for by law for failure to comply with Proposition 65 (assuming that Settling Defendants, at the relevant time, employ enough persons to qualify as a "[p]erson in the course of doing business" within the meaning of Health and Safety Code section 25249.11(a)), the Unfair Competition Law, the False Advertising Law, or any other laws. In any new action brought by the People or CSI or another enforcer alleging subsequent violations of law, Settling Defendants may assert any and all available defenses.

9

5

6

7

8

 ~ 1

2

3

4

in a contra de

8 AUTHORITY TO STIPULATE TO CONSENT JUDGMENT

8.1 Each signatory to the Stipulation portion of this Consent Judgment certifies that he
or she is fully authorized by the Party he or she represents to stipulate to this Consent Judgment
and to enter into the Consent Judgment on behalf of the Party he or she represents, respectively,
and to legally bind that Party.

14

9 CLAIMS COVERED

15 9.1 Full and Binding Resolution. This Consent Judgment is a full, final, and binding 16 resolution between both the People and CSI on the one hand, and on the other, Settling 17 Defendants, their parents, shareholders, divisions, subdivisions, subsidiaries, sister companies, 18 and cooperative members (collectively, the "Covered Entities"), and the officers, directors, 19 employees, attorneys, consultants, agents, representatives, predecessors, successors, and assigns 20 of any of the above, of any Causes of Action currently alleged in the Complaints. This Consent 21 Judgment resolves the claims applicable to the failure to warn for the presence of lead in the 22 Covered Products pled in the Complaints (i.e., the violation of Proposition 65 pled in the 23 Complaints by both the People and by CSI, and the violations of the Unfair Competition Law 24 pled by the People.)

9.2 <u>Downstream Entities</u>. This Consent Judgment also resolves the liability of all
entities who have purchased or received Covered Products sold or distributed by Settling
Defendants ("Downstream Entities"), including those Downstream Entities named as defendants
in the Complaints, for violations of Proposition 65 or the Unfair Competition Law for failure to

15

warn about alleged exposure to lead from use of the Covered Products that the Downstream Entities purchased from Settling Defendants prior to the Effective Date, including any exposure to lead from use of the Covered Products manufactured by Settling Defendants prior to the Effective Date. Downstream Entities include all such retail customers of Settling Defendants, including but not limited to, Target Corporation, Target Brands, Inc., Nurture, Inc., and Walmart, Inc.

 $\delta = 1 + 1 + 7$ 9.3 Following the Effective Date of this Consent Judgment, Compliance by Settling 8 Defendants with all of the requirements of this Consent Judgment, and Settling Defendants' full 9 cooperation in the implementation of this Consent Judgment, shall constitute compliance by .10 Settling Defendants with those provisions of Proposition 65 and the Unfair Competition law with 11 respect to any obligation to give warnings as to the lead content in any Covered Product. 12 Compliance by Settling Defendants with all of the requirements of this Consent Judgment 13 following the Effective Date constitutes compliance with Proposition 65 and the Unfair 14 Competition Law with respect to any obligation of Downstream Entities to provide a warning 15 under Proposition 65 as to the lead content of any Covered Product, provided that: Perrigo and 16 each Downstream Entity must provide any reasonably necessary cooperation in the 17 implementation of this Consent Judgment and they may not frustrate or interfere with the 18 implementation of any provision of this Consent Judgment.

9.4 Except as expressly provided herein, nothing in this Consent Judgment is intended
to, nor shall it be construed to, preclude the People, or any federal, state, or local agency,
department, board, or other entity, from exercising its authority or rights under any federal, state,
or local law, statute, or regulation. In any subsequent action that may be brought by the People or
CSI, Settling Defendants agree that they will not assert that failing to pursue such claim,
violation, or cause of action as part of this action constitutes claim-splitting.

9.5 This Consent Judgment resolves all claims relating to the failure to warn of the
presence of lead in the Covered Products. The People and CSI expressly retain the right to assert
any claims, whether under the Unfair Competition Law, the False Advertising Law, Proposition

28

 $1 \leq 1$

5

6

2

Intelly - Minnes 3

We as the set of the

and the second

where \mathbf{k}	65, or any other law or regulation, that do not arise from the failure to warn about the presence of
· · · · · · · · · 2	- lead in the Covered Products.
	10 NOTICE AND STATES AND IN NOTICE
4	When any Party is entitled to receive any notice under this Consent Judgment, the notice
5	shall be sent to the person and address set forth below:
6	To Settling Defendants:
7	Dennis Ragini
	Steptoe & Johnson LLP 633 W, Fifth Street, Suite 1900
9	Los Angeles, CA 90017 draglin@steptoe.com
10	Office of the General Counsel
11	Perrigo Company 515 Eastern Avenue
12	Allegan, MI 49010
13	To the People:
14	Megan Hey, Deputy Attorney General California Department of Justice
15	300 South Spring Street, Suite 1702 Los Angeles, CA 90013
16	Megan.Hey@doj.ca.gov
17	Matthew Beltramo, Deputy District Attorney Alameda County District Attorney's Office
18	7677 Oakport Street, Suite 650 Oakland, CA 94621
19	matt.beltamo@acgov.org
20	Caroline L. Fowler, Deputy District Attorney Sonoma County District Attorney's Office
21	Environmental Consumer Law Division 2300 County Center Drive, Suite B-170
22	Santa Rosa, Ca 95403
23	and the second and and an end of the second
24	To CSI:
25	Rebecca Davis
26	Lozeau Drury LLP 1939 Harrison Street, Suite 150 Octoberd, CA 04612
27	Oakland, CA 94612 rebecca@lozeaudrury.com
28	
	17

۰,

 s^{*}

Any Party may modify the person and address to whom the notice is to be sent by sending each other Party notice by e-mail or certified mail, return receipt requested. Said change shall take effect five days after the date the return receipt is signed by the Party receiving the notice, or immediately upon confirmation by e-mail from the Party receiving the notice.

11. WRITTEN CERTIFICATION.

11.1. Within fifteen (15) court days of the People's or CSI's written request, Settling Defendants will provide the People or CSI with written certification that any required action under this Consent Judgment has been taken or completed pursuant to the terms set forth herein.

9

. 1

2

4

5

6

7

8

and the state

3

12. MODIFICATION OF CONSENT JUDGMENT

10 12.1. After the Effective Date, this Consent Judgment may be modified from time to
11 time by: 1) express written agreement of the Parties with the approval of the Court; 2) an order of
12 this Court on noticed motion from the People, CSI, or Settling Defendants in accordance with
13 law, for good cause shown; or 3) the Court, pursuant to its inherent authority upon considering a
14 motion or request from a Party or the Parties.

15 12.2. Before filing an application with the Court for a modification to this Consent
16 Judgment, the Party seeking modification shall meet and confer with the other Parties to
17 determine whether the modification may be achieved by consent. If a proposed modification is
18 agreed upon, then Settling Defendants and the People, or Settling Defendants, the People and
19 CSI, or Settling Defendants and CSI, will present the modification to the Court by means of a
20 stipulated modification to the Consent Judgment.

21

13. REEVALUATION OF MAXIMUM LEAD LEVEL.

13.1. The Maximum Lead Level set forth in Section 3.6, above, as it applies to the
Covered Products, shall be subject to reevaluation if the People or CSI determine: (i) that it is
feasible, through good manufacturing or good agricultural practices, to achieve lower levels of
lead; or (ii) that it is otherwise necessary to comply with the requirements of Proposition 65. If
the People determine that the Maximum Lead Level should be lowered, they shall meet and
confer with Settling Defendants in order to agree by stipulation on a revised level and to other
changes to this Consent Judgment that result from lowering the Maximum Lead Level. If that

18

process is not successful, the People or CSI may seek to revise the Maximum Lead Level and make related changes by making a noticed motion in this Court.

13.2. Such a motion shall contain evidence from a qualified expert supporting the People's (and/or CSI's) claim that a lower level is available and feasible. In response to such a motion, Settling Defendants will have the opportunity to request that the Court permit limited written and deposition discovery of the People's expert(s). Settling Defendants may base their opposition to Plaintiff's motion on (i) this limited discovery; (ii) any other admissible evidence supporting its claim that a lower level is available and commercially feasible; and (iii) any applicable affirmative defenses.

10

17

26

8

9

5

istration while of

3

4

6

7

14. NO EFFECT ON OTHER PRODUCTS

The Maximum Lead Level defined herein is not applicable to products that are not subject to this Consent Judgment, and it is not intended to establish applicable or unacceptable lead levels for any such products. The People, and CSI, without limitation, expressly reserve the right to take action, seek penalties and injunctive relief, and exercise their authority or rights under any federal, state, or local law, statute, or regulation with regard to any products other than the Covered Products.

15. NO WAIVER OF THE RIGHT TO ENFORCE

18 The failure of the People, or of CSI, to enforce any provision of the Consent Judgment 19 shall neither be deemed a waiver of such provision, nor in any way affect the validity of the 20 Consent Judgment or enforcement authority of either the People or CSI. The failure of the 21 People or CSI to enforce any such provision in the Consent Judgment shall not preclude them 22 from later enforcing the same or other provisions. No oral advice, guidance, suggestions, or 23 comments by the People, or CSI, or Settling Defendants, or by people or entities acting on behalf 24 of any of them, regarding matters covered in this Consent Judgment, shall be construed to relieve 25 Settlement Defendants of their obligations under this Consent Judgment.

16. COURT APPROVAL

This Consent Judgment shall be submitted to the Court for entry by the Court. If this
Consent Judgment is not entered by the Court, it shall be of no force or effect, and may not be

19

$\partial \phi_{ij} \partial \phi_{ij} = \phi_{ij} + \phi_{ij} +$	used by the People or Settling Defendants for any purpose. If the Court does not approve this
2.	Consent Judgment, any money paid by Settling Defendants pursuant to Section 6 and held in trust
serie	by the People and/or CSI will be returned to Settling Defendants.
a ²²	17. ENTIRE AGREEMENT
	This Consent Judgment contains the sole and entire agreement and understanding of the
·	Parties with respect to the entire subject matter hereof, and any and all prior discussions,
7.	negotiations, commitments and understandings related hereto. No representations, oral or
	otherwise, express or implied, other than those contained herein have been made by any Party
9	hereto. No other agreements not specifically referred to herein, oral or otherwise, shall be deemed
10	to exist or to bind any of the Parties.
11	18. RETENTION OF JURISDICTION
12	This Court shall retain jurisdiction of this matter to implement and enforce the Consent
13	Judgment, and to resolve any disputes that may arise as to the implementation of this Consent
14	Judgment. Should a dispute arise as to the implementation of this Consent Judgment, any Party
15	may, by noticed motion, request that the Court resolve the dispute. If the dispute involves a
16	determination made by the People pursuant to Section 7 of this Consent Judgment, the Party
. 17	objecting to that determination will have the burden of challenging it.
18	19. SEVERABILITY
19	If, subsequent to the entry of this Consent Judgment, any of its provisions are held by any
20	court to be unenforceable, the validity of the enforceable provisions remaining shall not be
21	adversely affected.
22	20. EQUAL AUTHORSHIP
23	This Consent Judgment shall be deemed to have been drafted equally by the Parties
24	hereto. The Parties agree that the rule of construction holding that ambiguity is construed against
25	the drafting Party shall not apply to the interpretation of this Consent Judgment.
26	اليان المراجع المعالية 1987 (1987 (1987 (1987 (1987 (1997 − 1997 (1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1 المحالية المحالية (1997 (1997 (1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997 − 1997
27	
28	
	20

EXECUTION IN COUNTERPARTS

The stipulations to this Consent Judgment may be executed in counterparts and by means of facsimile, which taken together shall be deemed to constitute one document.

IT IS SO ORDERED and ADJUDGED:

1

2

3

4

5

6

7

11

DATED

ERIOR COURT JUDGE O

ROB BONTA Attomey General of California LAURA J. ZUCKERMAN Supervising Deputy Attorney General

DENNIS A. RAGEN MEGAN HEY Deputy Attorney General Attorneys for the People of the State of California

JILL R. RAVITCH SONOMA COUNTY DISTRICT ATTORNEY

Month T. By:

Matthew T. Cheever **Deputy District Attorney** Attorneys for the People of the State of California


NANCY E. O'MALLEY ALAMEDA COUNTY DISTRICT ATTORNEY

By:


Matthew Beltramo Assistant District Attorney Attorneys for the People of the State of California


ALC: YES	and the first state of the stat	and the second	
a de la compansión de la c	Dated: 10/29,2021	NAFA COUNTI DISTRICT ATTORNET	ļ.
2 3 4	na konstructivni stani sta Na seki stati stani s	By: Princik Collins Deputy District Attorney Attorneys for the People of the State of California	
5	Dated:, 2021		
7		ATTORNEY	
8 9 10		By: Douglas Allen DeputyAssistant District Attorney Attorneys for the People of the State of California	
11 12	Dated:, 2021	LORI FRUGOLI MARIN COUNTY DISTRICT ATTORNEY	
13 14 15		By: Andres Perez Deputy District Attorney Attorneys for the People of the State of	
16 17	Dated:, 2021	JEANNINE PACIONI MONTEREY COUNTY DISTRICT	
18 19	×	ATTORNEY By:	
20 21		Christopher Judge Deputy District Attorney Attorneys for the People of the State of California	
22 23	Dated:, 2021	TODD SPITZER ORANGE COUNTY DISTRICT	
24		ATTORNEY By:	
25 26		Jennifer Malone Deputy District Attorney Attorneys for the People of the State of	
27		California	
20		22	
		CONSENT JUDGMENT (RG18912553)	

the second the sum



Dated:	, 2021	ALLISON HALEY NAPA COUNTY DISTRICT ATTORN
		By: Patrick Collins Deputy District Attorncy Attorneys for the People of the State California
Dated:	,2021	JEFFREY ROSELL SANTA CRUZ COUNTY DISTRICT ATTORNEY
		By: Douglas Allen DeputyAssistant District Attorney Attorneys for the People of the State California
Dated: <u>10 -2 9</u>	, 2021	LORI FRUGOLI MARIN COUNTY DISTRICT ATTORNEY
		By: Curdues H. Ferey Andres Perez Deputy District Attorney Attorneys for the People of the State California
Dated:	, 2021	JEANNINE PACIONI MONTEREY COUNTY DISTRICT ATTORNEY
		Ву:
		Christopher Judge Deputy District Attorney Attorneys for the People of the State California
Dated:	, 2021	TODD SPITZER ORANGE COUNTY DISTRICT ATTORNEY
		By:
а — С Э	asiri, e. A. ∙	Jennifer Malone Deputy District Attorney
	state to the state	Attorneys for the People of the State California
	41 × 1 × g	- Parts Tan Angun Gravega
	×	22







Dated: 10-29,2021	JEFFREY F. ROSEN
, 2021	SANTA CLARA COUNTY DISTRICT
and a star with a second s	By: Q-A
	Jennifer Deng
	Deputy District Attorney Attorneys for the People of the Stat
	California
Dated:, 2021	STEPHANIE BRIDGETT
	SHASTA COUNTY DISTRICT ATTORNEY
	Ву:
	Anand "Lucky" Jesrani Senior Deputy District Attorney
	Senior Deputy District Attorney Attorneys for the People of the Sta California
Dated: , 2021	
Dated:, 2021	KRISHNA ADAMS SOLANO COUNTY DISTRICT
	ATTORNEY
	By:
	Diane Newman Deputy District Attorney
	Attorneys for the People of the Sta California
Dated:, 2021	LOZEAU DRURY LLP
	REBECCA L. DAVIS Attorneys for CSI
SIGNATURES CONTIUTED ON NEXT	1998 BC
· · · · ·	
· · · · · · · · · · · · · · · · · · ·	
B	
· · · ·	
and the second s	23


Ś.,

12

÷







DocuSign Envelope ID: 0C6FFE19-E028-4D1A-A27A FA5EDCF18B2B

Dated: ______ October 27 , 2021

PERRIGO CO., PBM PRODUCTS, LLC and PBM NUTRITIONALS, LLC

By: Todd Kingma Todd Kingma Executive Vice President and General Counsel PERRIGO COMPANY

STEPTOE & JOHNSON, LLP

Dennis ErRagin) Attorneys for Dendants Perrigo Company, PBM Products, LLC and PBM Nutritionals, LLP

By:

Dated: October 28.2021

Doc # 1.A/24077644v1

EXHIBIT A

EXHIBIT A

AUDITOR'S CERTIFICATION

[Name] , certify as follows with respect to the following Covered Products:

INSERT NAMES OF PRODUCTS

I. <u>DEFINITIONS</u>

For the purposes of this Certification, the following definitions are applicable:

- A. "<u>Consent Judgment</u>" means the Consent Judgment entered into by the People and Perrigo Company (Perrigo) in Alameda County Superior Court, Case No. RG18407841, on [DATE].
- B. "<u>Covered Products</u>" means the Products identified in Section 3.1 of the Consent Judgment that were manufactured after the Effective Date.
- C. The "<u>Maximum Lead Level(s)</u>" shall mean 7 parts per billion (ppb) for soy-based formulas and 5 ppb for all other Covered Products.
- D. The "<u>Target Lead Level</u>" -shall mean-the lead level set for each Covered Product, or group of similar Covered Products, based on the Lead Contribution Exercise and the Internal Auditor's review of the lowest lead levels that can be achieved by commercially reasonable means, pursuant to Sections 3.7 and 5.1(3) of the Consent Judgment.
- E. A "<u>Qualified Laboratory</u>" is a laboratory that meets the requirements, and follows the procedures, set forth in Exhibit B to the Consent Judgment.
- F. A "Lead Contribution Exercise" is a mass balance exercise that evaluates the contribution of lead from each ingredient that has the potential to contribute a significant amount of lead to the Covered Products pursuant to the risk assessment analysis conducted by Settling Defendants as part of its Hazard Analysis and Critical Control Points ("HACCP") program. The objective of the Lead Contribution Exercise is to calculate the potential total amount of lead that will result from the formulation of the product, considering: (1) the amount of each ingredient present in the finished product, and (2) the amount of lead present in each such ingredient, based on laboratory testing or other reliable information or evidence regarding the lead levels in each such ingredient. The resulting calculation of the total lead concentration in the product is then compared with the maximum amount of lead allowed. If the formulation of the product results in a lead concentration that exceeds the Target

Lead Level, then the formulation and/or the lead content of the ingredients must be changed to meet the Target Lead Level.

The Auditor will conduct the Lead Contribution Exercise for the Covered Products. Based on the Lead Contribution Exercise, the Auditor will establish maximum lead concentrations for each ingredient that has the potential to cause the finished Covered Product, or group of similar Covered Products, to exceed the Target Lead Level. The lead concentrations that the Auditor establishes as part of the Lead Concentration Exercise must be designed to result in finished Covered Products that have lead concentrations that satisfy the applicable Target Lead Level.

- G. "<u>Representative Samples</u>" shall mean six (6) samples, as described in Section 4.2 of the Consent Judgment, from at least the following manufacturing lots:
 - 1. For purposes of the initial certification that a Covered Product complies with the Maximum Lead Level: six (6) consecutive lots of the Covered Product that were manufactured after the Effective Date or after the date that a new Covered Product is initially sold.
 - 2. For subsequent certifications of the Maximum Lead Level for each Covered Product: the greater of
 - (i) six (6) lots of that Covered Product that are manufactured during the annual validation testing cycle, or
 - (ii) either (A) a number of lots equal to the square root, rounded up to the nearest whole number, of the total number of lots that are manufactured during the annual validation testing cycle, or (B) at least the first three lots of that Covered Product manufactured during that cycle, followed by testing of every fourth lot thereafter.

If a lot fails to satisfy the Maximum Lead Level, Settling Defendants must reevaluate their controls, and then show that the following number of lots satisfy the Maximum Lead Level before reverting to testing the lots as specified in sections 2(i) and (ii) above:

- (a) Where more than six (6) lots of a Covered Product are manufactured during the annual validation cycle, Settling Defendants shall test at least the first two lots and then every second lot thereafter until a total of six (6) lots have been tested;
- (b) Where six (6) or fewer lots of a Covered Product are manufactured during than cycle, each lot shall be tested.
- H. "Effective Date" has the same meaning as in the Consent Judgment, i.e., the date on which the Consent Judgment is entered as a judgment by the Court.

II. CERTIFICATION

- 1. <u>HAACP Program</u>. Perrigo has implemented a Hazard Analysis and Critical Control Points ("HACCP") program that identifies lead as a hazard and implements prevention steps to minimize the presence of lead in the Covered Products.
- 2. <u>Certifications</u>. Based on my review of Perrigo's facilities, I certify that Perrigo satisfies the following requirements ("Lead Reduction Requirements") in its production of the Covered Products:
 - 2.1. <u>Potable Water Supply</u>. The potable water supply is monitored for lead levels. The internal distribution system is not a source of lead contamination.
 - 2.2. <u>Food Contact Surfaces</u>. All food and ingredient contact equipment, utensils and containers are constructed from lead-free materials. No brass or bronze components may come in contact with ingredients or the final product. (Evidence of the use of lead-containing materials, as verified using a LeadCheck Swab, XRF lead testing device, or a similar test method, is considered a critical deficiency).
 - 2.3. <u>Lubricants/Sealants, etc.</u> Lubricants, sealants and similar materials used in direct food contact areas, as well as in areas that have the potential to contaminate product, are food grade. This included storage areas in addition to processing and packing areas.
 - 2.4. <u>Preventative devices</u>. Preventative devices including screens, filters, magnets, metal detection devices, and manual inspection are used to remove foreign material (metal, wood, plastic, etc).
 - 2.5. <u>Process control</u>. Process control is validated through an audit program whereby processes and finished product is periodically tested for total lead content. The Limit of Quantification (LOQ) for the finished products and major ingredients must be equal to or less than 0.001 mg/kg.
 - 2.6. Lot identification/Traceability. Lot identification and traceability is maintained for major and minor ingredients and processing aids. The manufacturer is able to document the major and minor ingredients lots used to produce specific finished product lots and to trace finished product shipments one level forward to the customer.
 - 2.7. <u>Standard GMPs</u>. Perrigo has established Good Manufacturing Practices for the Covered Products, that include the following, which are continuously in place:
 - 2.7.1. Specifications are established for controlled manufacturing steps.
 - 2.7.2. Master manufacturing records and batch production records are prepared and maintained.

Exhibit A – Page 3

- 2.7.3. Standard Operating Procedures ("SOPs") are prepared to cover the quality control operations, including the calibration and control of equipment and instruments used in manufacturing.
- 2.7.4. SOPs are established and reviewed for investigation of product complaints.
- 2.7.5. Annual Audit. Perrigo undergoes an annual audit by a third party auditor to verify that its GMP and HACCP programs are effectuated with respect to facilities producing the Covered Products.
- <u>Target Lead Levels</u>. I set the following Target Lead Levels for each Covered Product or group of similar Covered Products. [Insert Target Lead Levels]
- 4. <u>Testing and Follow-Up for Covered Products</u>. In order to ensure that lead levels in the Covered Products do not exceed the applicable Maximum Lead Levels, I have taken the following steps:
 - 4.1. <u>Testing Representative Samples</u>. Representative samples of the Covered Product have been tested in compliance with Section 4.2.2 of the Consent Judgment, and the Analytical Guidance for Laboratories set forth in Exhibit B.
 - 4.2. <u>Results Exceeding Maximum Lead Level [If Applicable Pursuant to Section 4.5 of the</u> <u>Consent Judgment]</u>. This testing indicated that the lead levels in the following products exceeded the applicable Maximum Lead Level. [Insert Product Names, if any]
 - 4.2.1. <u>Follow Up Measures</u>. [*If Applicable*] With respect to these products, Perrigo has complied with, or is currently in the process of complying with, the requirements set forth in Section 4.5 of the Consent Judgment, as follows: [Describe steps taken to comply with Section 4.3.1 of the Consent Judgment.]
 - 4.2.2. <u>Follow-Up Measures</u>. For soy-based formulas that have lead concentrations that exceed or are likely to exceed 5 ppb, Perrigo has taken the following steps: [Describe steps taken to comply with Section 4.6 of the Consent Judgment.]
- 5. Lead Contribution Exercise. I have conducted Perrigo's Lead Contribution Exercise for existing and newly-created Covered Products. Based on the Lead Contribution Exercise described in Section F above, and the Target Lead Levels described in Section 3.7 and 5.1(3) of the Consent Judgment and in section 3, above, I established maximum lead concentrations for the following ingredients: [Insert ingredients and maximum lead concentrations]. The lead concentrations that I established as part of the Lead Concentration Exercise are designed to result in finished Covered Products with lead concentrations of no more than the applicable Target Lead Level.
- 6. <u>Ingredient Certification or Testing</u>. With respect to ingredients that are likely to contribute lead in amounts that that can cause the finished product to exceed the applicable Target Lead

Exhibit A – Page 4

Level, Perrigo has taken the following steps to ensure that those ingredients do not contain lead in excess of the applicable maximum lead concentrations established pursuant to Sections F, 3 and 5, above: [Describe steps which include Perrigo's testing of ingredients, or reliable testing, or certification of the ingredients by the suppliers.]

2. 8.

7. <u>Independent Food Quality Auditor</u>. [For the First Annual Certification:] This certification has been reviewed by a qualified Independent Food Quality Auditor who has been given site access and data necessary for that review.

DATE:

SIGNATURE OF PERRIGO INTERNAL AUDITOR.

EXHIBIT B

이 이상 방법에 있는 것이 있는 것이 가지 않는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있다. 가지 않는 것이 있는 같은 것이 같은 것이 있는 것 같은 것은 것은 것이 같은 것이 있는 것이 같은 것이 같은 것이 있는 것

<u>Exhibit B</u>

Analytical Guidance for Laboratories.

Analyses must utilize a method that employs ICP-MS. Laboratories must have the capability of controlling lead contamination throughout the analytical process, including sample compositing, sample digestion, and the lead determination steps. In order to meet the analytical objectives, the use of high purity acids will be required as well the use of closed-vessel type sample digestion procedures. The conditions and procedures needed to successfully meet the analyses are described in the FDA Elemental Analysis Manual, EAM 4.7.

https://www.fda.gov/food/laboratory-methods-food/elemental-analysis-manual-eam-food-and-related-products

https://www.fda.gov/media/87509/download

Particular attention must be given to the specifications for recovery determinations offered to attribute accuracy to these analyses. The levels of lead used to fortify products and ingredients for analyte recovery must be in the range of 50-200% of the lead level found in the product, if the level of lead in the product is in a quantifiable range. As a measure of accuracy, laboratories are also encouraged to provide recovery information for Certified Reference Materials with a matrix like that of the sample and with similar lead levels.

Participating laboratories must be accredited, preferably under ISO 17025 to conduct low level lead analyses in foods by ICP-MS.

The analytical objective for lead analysis, i.e., the Limit of Quantification (LOQ), for finished products and for the major ingredients is 0.001 mg/kg, or less.

Test results shall be the average of the triplicate analysis conducted by the laboratory.

The analytical results from the laboratory shall include the: limit of detection; limit of quantitation; spike recovery; blanks; method validation and other quality control parameters; and the statistical variance within the method (typically 10% or one sigma of the results).

The laboratory must participate in a valid check sample program.

EXHIBIT C

Exhibit C

Payment Detail

Payee	Address	Description	Amount
Office of Environmental	Senior Accounting Officer – MS 19-B		
Health Hazard Assessment	Office of Environmental Health Hazard Assessment P.O. Box 4010 Sacramento, CA 95812-0410	Civil Penalty	\$54,375.00
Attorney General	Robert Thomas Legal Analyst	Civil Penalty	9,062.50
	1515 Clay St., 20th Floor	Fees/Costs	45,000.00
	P.O. Box 70550 Oakland, CA 94612-0550	Total	54,062.50
Monterey County District Attorney	Christopher Judge Deputy District Attorney	Civil Penalty	72,500.00
to be distributed	1200 Aguajito Road, Room 301, Monterey, CA 93940	Fees/Costs	30,000.00
to California FDMD Task Force		Total	102,500.00
Community Science Institute	Rebecca L. Davis Lozeau, Drury LLP 1939 Harrison St., Suite 150 Oakland, CA 94612	Civil Penalty	9,062.50
		Fees/Costs	140,000.00
		Total	149,062.50

Copies of all checks will be sent to:

Megan Hey Deputy Attorney General Office of the CA Attorney General 300 South Spring Street Los Angeles, CA 90013